Want to download this as a PDF? Download now
EU Clinical Trials Register EudraCT number 2018-001795-38
CHIEF INVESTIGATOR: MD PhD Mats Marshall Heyman, Karolinska University Hospital, Sweden
The primary objective of ALLTogether1 is to improve survival and quality of life in children and young adults with ALL. A sub-group of patients that may benefit from novel immunotherapy could be identified. The recruitment started in 2021 and will continue until at least May 2027.
The main treatment for ALL is chemotherapy, with a variety of drugs prescribed in different combinations, depending on the patient enrolled. Chemotherapy usually works well for children and young adults with ALL.
However, a better patient risk stratification would improve treatment plans and oncological outcomes, meaning less chemotherapy and reduced toxicity to patients in the low-risk group. The trial uses a combination of several factors to stratify patients into risk groups, determining the treatment they shall receive. This process includes investigating the cytogenetic abnormalities in leukaemic cells.<1,2
Figure 1. Acute lymphoblastic leukaemia FISH test algorithm
Table 1. CytoCell® IVD products that support the ALLTogether1 genetic risk stratification algorithm protocol implementation
Table 2. Other CytoCell probes and CytoCell myProbes®, custom FISH probes that may aid in ALL research
myProbes: For Research Use Only; Not for Use in Diagnostic Procedures. CytoCell: Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representatives for availability.